|
1
|
Wang LD, Qin YR, Fan ZM, et al:
Comparative genomic hybridization: comparison between esophageal
squamous cell carcinoma and gastric cardia adenocarcinoma from a
high-incidence area for both cancers in Henan, northern China. Dis
Esophagus. 19:459–467. 2006. View Article : Google Scholar
|
|
2
|
Devesa SS, Blot WJ and Fraumeni JF Jr:
Changing patterns in the incidence of esophageal and gastric
carcinoma in the United States. Cancer. 83:2049–2053. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Botterweck AA, Schouten LJ, Volovics A,
Dorant E and van Den Brandt PA: Trends in incidence of
adenocarcinoma of the oesophagus and gastric cardia in ten European
countries. Int J Epidemiol. 29:645–654. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kadomatsu K and Muramatsu T: Midkine and
pleiotrophin in neural development and cancer. Cancer Lett.
204:127–143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhao ZQ, Yang S and Lu HS: Expression of
midkine and vascular endothelial growth factor in gastric cancer
and the association of high levels with poor prognosis and
survival. Mol Med Rep. 5:415–419. 2012.PubMed/NCBI
|
|
6
|
Huang Y, Cao G, Wang H, Wang Q and Hou Y:
The expression and location of midkine in gastric carcinomas of
Chinese patients. Cell Mol Immunol. 4:135–140. 2007.PubMed/NCBI
|
|
7
|
Muramatsu T: Midkine, a heparin-binding
cytokine with multiple roles in development, repair and diseases.
Proc Jpn Acad Ser B Phys Biol Sci. 86:410–425. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muramatsu T: Midkine and pleiotrophin: two
related proteins involved in development, survival, inflammation
and tumorigenesis. J Biochem. 132:359–371. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mitsiadis TA, Salmivirta M, Muramatsu T,
et al: Expression of the heparin-binding cytokines, midkine (MK)
and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal
interactions during fetal development and organogenesis.
Development. 121:37–51. 1995.
|
|
10
|
Bernfield M, Kokenyesi R, Kato M, et al:
Biology of the syndecans: a family of transmembrane heparan sulfate
proteoglycans. Annu Rev Cell Biol. 8:365–393. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Teng YH, Aquino RS and Park PW: Molecular
functions of syndecan-1 in disease. Matrix Biol. 31:3–16. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Anttonen A, Kajanti M, Heikkilä P,
Jalkanen M and Joensuu H: Syndecan-1 expression has prognostic
significance in head and neck carcinoma. Br J Cancer. 79:558–564.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hirabayashi K, Numa F, Suminami Y, et al:
Altered proliferative and metastatic potential associated with
increased expression of syndecan-1. Tumour Biol. 19:454–463. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harada K, Masuda S, Hirano M and Nakanuma
Y: Reduced expression of syndecan-1 correlates with histologic
dedifferentiation, lymph node metastasis, and poor prognosis in
intrahepatic cholangiocarcinoma. Hum Pathol. 34:857–863. 2003.
View Article : Google Scholar
|
|
15
|
Wu X, Chen VW, Andrews PA, Ruiz B and
Correa P: Incidence of esophageal and gastric cancers among
Hispanics, non-Hispanic whites and non-Hispanic blacks in the
United States: subsite and histology differences. Cancer Causes
Control. 18:585–593. 2007. View Article : Google Scholar
|
|
16
|
Wijetunge S, Ma Y, DeMeester S, et al:
Association of adenocarcinomas of the distal esophagus,
‘gastroesophageal junction,’ and ‘gastric cardia’ with gastric
pathology. Am J Surg Pathol. 34:1521–1527. 2010.PubMed/NCBI
|
|
17
|
Xiao ZY, Ru Y, Sun JT, et al: Expression
of CDX2 and villin in gastric cardiac intestinal metaplasia and the
relation with gastric cardiac carcinogenesis. Asian Pac J Cancer
Prev. 13:247–250. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ding GC, Ren JL, Chang FB, et al: Human
papillomavirus DNA and P16(INK4A) expression in concurrent
esophageal and gastric cardia cancers. World J Gastroenterol.
16:5901–5906. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chu YQ, Ye ZY, Tao HQ, et al: Relationship
between cell adhesion molecules expression and the biological
behavior of gastric carcinoma. World J Gastroenterol. 14:1990–1996.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Obata Y, Kikuchi S, Lin Y, et al: Serum
midkine concentrations and gastric cancer. Cancer Sci. 96:54–56.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sakamoto K and Kadomatsu K: Midkine in the
pathology of cancer, neural disease, and inflammation. Pathol Int.
62:445–455. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Michikawa M, Kikuchi S, Muramatsu H,
Muramatsu T and Kim SU: Retinoic acid responsive gene product,
midkine, has neurotrophic functions for mouse spinal cord and
dorsal root ganglion neurons in culture. J Neurosci Res.
35:530–539. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shimada H, Nabeya Y, Okazumi S, et al:
Increased serum midkine concentration as a possible tumor marker in
patients with superficial esophageal cancer. Oncol Rep. 10:411–414.
2003.PubMed/NCBI
|
|
24
|
Xu YY, Mao XY, Song YX, et al: Midkine
confers Adriamycin resistance in human gastric cancer cells. Tumour
Biol. 33:1543–1548. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Krzystek-Korpacka M, Diakowska D,
Grabowski K and Gamian A: Tumor location determines midkine level
and its association with the disease progression in colorectal
cancer patients: a pilot study. Int J Colorectal Dis. 27:1319–1324.
2012. View Article : Google Scholar
|
|
26
|
Hung YJ, Lin ZH, Cheng TI, Liang CT, Kuo
TM and Kao KJ: Serum midkine as a prognostic biomarker for patients
with hepatocellular carcinoma. Am J Clin Pathol. 136:594–603. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao G, Nie Y, Lv M, He L, Wang T and Hou
Y: ERβ-mediated estradiol enhances epithelial mesenchymal
transition of lung adenocarcinoma through increasing transcription
of midkine. Mol Endocrinol. 26:1304–1315. 2012.
|
|
28
|
Ibusuki M, Fujimori H, Yamamoto Y, et al:
Midkine in plasma as a novel breast cancer marker. Cancer Sci.
100:1735–1739. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reiff T, Huber L, Kramer M, Delattre O,
Janoueix-Lerosey I and Rohrer H: Midkine and Alk signaling in
sympathetic neuron proliferation and neuroblastoma predisposition.
Development. 138:4699–4708. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fabri L, Maruta H, Muramatsu H, et al:
Structural characterisation of native and recombinant forms of the
neurotrophic cytokine MK. J Chromatogr. 646:213–225. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao ZQ, Yang S, Lu HS, et al: Expression
of midkine and vascular endothelial growth factor in gastric cancer
and the association of high levels with poor prognosis and
survival. Mol Med Rep. 5:415–419. 2012.PubMed/NCBI
|
|
32
|
Teng YH, Aquino RS and Park PW: Molecular
functions of syndecan-1 in disease. Matrix Biol. 31:3–16. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fux L, Ilan N, Sanderson RD and Vlodavsky
I: Heparanase: busy at the cell surface. Trends Biochem Sci.
34:511–519. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang MF, Zhu YQ, Chen ZF, et al:
Syndecan-1 and E-cadherin expression in differentiated type of
early gastric cancer. World J Gastroenterol. 11:2975–2980. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Conejo JR, Kleeff J, Koliopanos A, et al:
Syndecan-1 expression is up-regulated in pancreatic but not in
other gastrointestinal cancers. Int J Cancer. 88:12–20. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wiksten JP, Lundin J, Nordling S, et al:
Epithelial and stromal syndecan-1 expression as predictor of
outcome in patients with gastric cancer. Int J Cancer. 95:1–6.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vlodavsky I, Friedmann Y, Elkin M, et al:
Mammalian heparanase: gene cloning, expression and function in
tumor progression and metastasis. Nat Med. 5:793–802. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Naggi A, Casu B, Perez M, et al:
Modulation of the heparanase-inhibiting activity of heparin through
selective desulfation, graded N-acetylation, and glycol splitting.
J Biol Chem. 280:12103–12113. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kato M, Wang H, Kainulainen V, et al:
Physiological degradation converts the soluble syndecan-1
ectodomain from an inhibitor to a potent activator of FGF-2. Nat
Med. 4:691–707. 1998. View Article : Google Scholar : PubMed/NCBI
|
